Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.780
-0.210 (-4.21%)
At close: Sep 11, 2026, 4:00 PM EDT
4.740
-0.040 (-0.83%)
After-hours: Sep 11, 2026, 7:39 PM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Aquestive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.33. The average 1-year stock price forecast is 95.19% higher than the current stock price, while the lowest is $6.00 (+25.52%) and the highest is $11 (+130.13%).
Price Target: $9.33 (+95.19%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aquestive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 | Buy | Reiterates | $10 | +109.21% | Aug 24, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +109.21% | Aug 13, 2026 |
| Lake Street | Lake Street | Buy Maintains $6 | Buy | Maintains | $6 | +25.52% | Aug 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $11 | Buy | Maintains | $11 | +130.13% | Jun 26, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $8 | Buy | Reiterates | $8 | +67.36% | Jun 25, 2026 |
Financial Forecast
Revenue This Year
49.93M
from 44.55M
Increased by 12.09%
Revenue Next Year
67.77M
from 49.93M
Increased by 35.73%
EPS This Year
-0.45
from -0.59
EPS Next Year
-0.57
from -0.45
EPS and Forward PE are based on non-GAAP adjusted numbers.